000150078 001__ 150078 000150078 005__ 20250130223147.0 000150078 0248_ $$2sideral$$a71699 000150078 037__ $$aART-2010-71699 000150078 041__ $$aeng 000150078 100__ $$aMartin, M. 000150078 245__ $$aAdjuvant docetaxel for high-risk, node-negative breast cancer 000150078 260__ $$c2010 000150078 5203_ $$aA regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as adjuvant therapy in women with node-positive breast cancer. The value of taxanes in the treatment of node-negative disease has not been determined. METHODS We randomly assigned 1060 women with axillary-node–negative breast cancer and at least one high-risk factor for recurrence (according to the 1998 St. Gallen criteria) to treatment with TAC or FAC every 3 weeks for six cycles after surgery. The primary end point was disease-free survival after at least 5 years of follow-up. Secondary end points included overall survival and toxicity. RESULTS At a median follow-up of 77 months, the proportion of patients alive and disease- free was higher among the 539 women in the TAC group (87.8%) than among the 521 women in the FAC group (81.8%), representing a 32% reduction in the risk of recurrence with TAC (hazard ratio, 0.68; 95% confidence interval [CI], 0.49 to 0.93; P = 0.01 by the log-rank test). This benefit was consistent, regardless of hormone- receptor status, menopausal status, or number of high-risk factors. The difference in survival rates (TAC, 95.2%; FAC, 93.5%) was not significant (hazard ratio, 0.76; 95% CI, 0.45 to 1.26); however, the number of events was small (TAC, 26; FAC, 34). Rates of grade 3 or 4 adverse events were 28.2% with TAC and 17.0% with FAC (P<0.001). Toxicity associated with TAC was diminished when primary prophylaxis with granulocyte colony-stimulating factor was provided. CONCLUSIONS As compared with adjuvant FAC, adjuvant TAC improved the rate of disease-free survival among women with high-risk, node-negative breast cancer 000150078 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000150078 590__ $$a53.486$$b2010 000150078 591__ $$aMEDICINE, GENERAL & INTERNAL$$b1 / 152 = 0.007$$c2010$$dQ1$$eT1 000150078 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000150078 700__ $$aSegui, M. A. 000150078 700__ $$0(orcid)0000-0002-9159-4988$$aAnton, A.$$uUniversidad de Zaragoza 000150078 700__ $$aRuiz, A. 000150078 700__ $$aRamos, M. 000150078 700__ $$aAdrover, E. 000150078 700__ $$aAranda, I. 000150078 700__ $$aRodriguez-Lescure, A. 000150078 700__ $$aGrosse, R. 000150078 700__ $$aCalvo, L. 000150078 700__ $$aBarnadas, A. 000150078 700__ $$aIsla, D. 000150078 700__ $$aMartinez Del Prado, P. 000150078 700__ $$aBorrego, M. R. 000150078 700__ $$aZaluski, J. 000150078 700__ $$aArcusa, A. 000150078 700__ $$aMunoz, M. 000150078 700__ $$aLopez Vega, J. M. 000150078 700__ $$aMel, J. R. 000150078 700__ $$aMunarriz, B. 000150078 700__ $$aLlorca, C. 000150078 700__ $$aJara, C. 000150078 700__ $$aAlba, E. 000150078 700__ $$aFlorian, J. 000150078 700__ $$aLi, J. 000150078 700__ $$aLopez Garcia-Asenjo, J. 000150078 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000150078 773__ $$g363, 23 (2010), 2200-2210$$pN. Engl. j. med.$$tNEW ENGLAND JOURNAL OF MEDICINE$$x0028-4793 000150078 8564_ $$s739523$$uhttps://zaguan.unizar.es/record/150078/files/texto_completo.pdf$$yVersión publicada 000150078 8564_ $$s2634514$$uhttps://zaguan.unizar.es/record/150078/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000150078 909CO $$ooai:zaguan.unizar.es:150078$$particulos$$pdriver 000150078 951__ $$a2025-01-30-20:32:09 000150078 980__ $$aARTICLE